Table 3.
Correlations matrix between activin A, follistatin and their ratio, and other study’s parameters for all NAFLD patients (n=31; sum of SS and NASH patients).
| Activin A (pg/ml) | Follistatin (ng/ml) | Activin A to Follistatin ratio |
|
|---|---|---|---|
| Age (years) | 0.32 (0.10) | −0.05 (0.79) | 0.22 (0.26) |
| BMI (kg/m2) | 0.51 (0.005)* | −0.04 (0.83) | 0.42 (0.026)* |
| Waist circumference (cm) | 0.12 (0.57) | 0.01 (0.95) | 0.14 (0.48) |
| AST (U/l) | 0.35 (0.06) | 0.17 (0.36) | 0.08 (0.67) |
| ALT (U/l) | −0.03 (0.87) | 0.26 (0.15) | −0.22 (0.26) |
| AST/ALT ratio | 0.51 (0.005)* | −0.14 (0.45) | 0.40 (0.031)* |
| GGT (U/l) | 0.21 (0.27) | 0.18 (0.34) | 0.04 (0.84) |
| Total cholesterol (mg/dl) | −0.35 (0.06) | 0.33 (0.07) | −0.43 (0.020)* |
| HDL-C (mg/dl) | 0.01 (0.97) | 0.14 (0.47) | −0.03 (0.89) |
| LDL-C (mg/dl) | −0.26 (0.18) | 0.27 (0.15) | −0.32 (0.09) |
| Triglycerides (mg/dl) | 0.06 (0.75) | 0.21 (0.25) | −0.17 (0.39) |
| Urea (mg/dl) | −0.31 (0.10) | −0.12 (0.51) | −0.14 (0.48) |
| Creatinine (mg/dl) | −0.31 (0.10) | −0.08 (0.66) | −0.17 (0.38) |
| Uric acid (mg/dl) | −0.27 (0.15) | −0.04 (0.85) | −0.17 (0.38) |
| Glucose (mg/dl) | 0.48 (0.009)* | 0.10 (0.58) | 0.19 (0.33) |
| Insulin (µU/ml) | 0.50 (0.006)* | 0.11 (0.55) | 0.24 (0.20) |
| HOMA-IR | 0.54 (0.003)* | 0.12 (0.51) | 0.27 (0.16) |
| Leptin (ng/ml) | 0.59 (0.001)* | 0.13 (0.48) | 0.31 (0.10) |
| Adiponectin (µg/ml) | 0.22 (0.25) | −0.50 (0.005)* | 0.48 (0.008)* |
| RBP-4 (µg/ml) | −0.31 (0.11) | 0.21 (0.27) | −0.36 (0.06) |
| Chemerin (ng/ml) | 0.32 (0.09) | 0.12 (0.54) | 0.02 (0.92) |
| Irisin (ng/ml) | −0.29 (0.13) | 0.28 (0.12) | −0.33 (0.09) |
| Activin A (pg/ml) | - | −0.10 (0.59) | 0.67 (<0.001)* |
| Follistatin (ng/ml) | - | - | −0.76 (<0.001)* |
Data are presented as Spearman’s rho coefficient (p-value).
*
: Correlations with p-value<0.05.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; GGT, gamma-glutamyl transferase; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostatic model of assessment insulin resistance; LDL-C, low density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; RBP, retinol-binding protein; SS, simple steatosis.